Raymond James Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $135 to $145.
November 01, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $135 to $145, which could lead to a positive impact on the stock.
The raised price target by Raymond James indicates a positive outlook for Neurocrine Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100